

AIRWAY CONDITIONING ENHANCES LONG-TERM LENTIVIRAL REPORTER GENE EXPRESSION

Robinson

THE UNIVERSITY
OF ADLAIDE

Institute



Sharon S. Smith^{1,2}, Daniel J. Exley³, Patricia Umielewski^{1,2}, Martin C. McElroy^{1,2}, Peter D. Bell^{1,2}, Nigel Farrow^{1,2}, Jill Lipsett³ and David Parsons^{1,2}

1. Respiratory and Sleep Medicine, Women's and Children's Hospital, South Australia
2. Robinson Research Institute, University of Adelaide, South Australia
3. School of Paediatrics and Reproductive Health, University of Adelaide, South Australia
4. Centre for Stem Cell Research, University of Adelaide, South Australia
5. SA Pathology, Women's and Children's Hospital, South Australia

Women's

Government of South Australia



Lentiviral (LV) gene vectors pseudotyped with the vesicular stomatitis virus G glycoprotein (VSV-G) have the potential to treat cystic fibrosis (CF) long-term. However physiological barriers of the airway prevent efficient vector access to the receptors on the basolateral surface of ciliated and basal (stem) cells residing on the basement membrane.

A 20 μ l bolus of a HIV-1 LV vector carrying the LacZ transgene was instilled directly into the trachea of C57BL/6 mice (n=10 per group) via orotracheal intubation, 1 hour after a pre-treatment with either 15 μ g PBS (control), 0.1% LPC or 0.3% LPC.

We have demonstrated the effectiveness of our lysophosphatidylcholine (LPC) conditioning pre-treatment and VSV-G LV vector dosing.

The aim of this experiment was to determine if LPC conditioning enhances LV reporter gene transduction in mouse lung conducting airways, since it is the primary target of CF genes that are expressed in the lung.

RESULTS:

Dosing was well tolerated, however there was a mild transient respiratory depression at the time of LV delivery.

There was little/no LacZ transduction in the control group that received the PBS pre-treatment (Fig. 1a), however there was a consistent pattern of strong LacZ transduction of the conducting airways in both LPC treatment groups (Fig. 1b &c).

Histological staining of lung sections revealed a significant difference in the number of LacZ transduced cells/mm of cartilaginous-associated upper airways from both LPC treatment groups compared to PBS ($p<0.01$ and $p<0.05$, ANOVA 0.1% LPC and 0.3% LPC respectively, Fig. 2).

The majority of cell transduction occurred in ciliated epithelial cells, with some basal cell transduction also present (Fig. 3).

Few LacZ stained cells were noted in the peripheral airways from any treatment.




Figure 1. Example of lung LV-LacZ transduction of conducting airways at 3 months following a) control PBS, b)

CONCLUSION:

LPC conditioning prior to LV vector delivery used by other research groups is sufficient for producing extended lung expression. Serial side-effects from use of higher LPC doses (> 0.3%) may limit its use, so the highest dose that can induce the normal airway responses (i.e. 0.1% to 0.3%) is recommended. The LPC conditioning groups also showed basal cell transduction, consistent with the ability to target basal stem cells in the normal airways. The National Health and Medical Research Council of Australia and the Cystic Fibrosis Foundation of America funded this work.

ACKNOWLEDGEMENTS: